MARKET
IPO

RCHR

ArcherDX, Inc.
RCHR
NASDAQ
Upcoming IPOs
Expected Listing Date: - -
P/E
P/S
P/B
MARKET CAP
INDUSTRY
-
-
-
-
Biotechnology & Medical Research
2020-06-05
Public Filing
View Prospectus
Pending
Offering
Price Range: Pending
Shares to be Issued: Pending
Pending
Offering End Date
Offering Price: Pending
Post IPO Outstanding: Pending
Listed
No Data
About RCHR
ArcherDX, Inc. is a genomics company. The Company’s product development platform, with its anchored multiplex polymerase chain reaction (AMP), enables to develop products and services that allow for therapy optimization and cancer monitoring. The Company offers research use only (RUO) products, in-vitro diagnostic (IVD) products and services for clinical applications. Its RUO product lines consist of deoxyribonucleic acid (DNA)-based VariantPlex, ribonucleic acid (RNA)-based FusionPlex, circulating tumor DNA (ctDNA)-based LiquidPlex and RNA-based Immunoverse, and personalized cancer monitoring (PCM). The Company's offerings include commercial RUO products and services that laboratories use to conduct genomic analysis for therapy optimization and cancer monitoring. The Company’s modular product development platform combines its AMP chemistry, target-specific primers, ancillary reagents, and bioinformatics software to detect mutations.

Webull offers ArcherDX, Inc. stock information, including NASDAQ: RCHR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RCHR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading RCHR stock methods without spending real money on the virtual paper trading platform.